Compare PEW & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEW | ACET |
|---|---|---|
| Founded | 2007 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 83.3M |
| IPO Year | 2025 | 2017 |
| Metric | PEW | ACET |
|---|---|---|
| Price | $2.31 | $9.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.75 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 237.9K | 74.1K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,449,000.00 | N/A |
| Revenue This Year | $5.25 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.57 | N/A |
| 52 Week Low | $2.22 | $0.46 |
| 52 Week High | $6.76 | $9.97 |
| Indicator | PEW | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 58.39 |
| Support Level | $2.25 | $7.45 |
| Resistance Level | $2.75 | $9.59 |
| Average True Range (ATR) | 0.08 | 0.52 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 24.37 | 66.67 |
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).